|Articles|April 22, 2014
- March/April 2014
- Volume 5
- Issue 2
Patent Expirations Expected to Cause Boom in Biosimilars Market
Author(s)Davy James, Associate Editor
Advertisement
The global biosimilars market is projected to experience significant growth over the next several years, according to a report from TechNavio.
The report, Global Biosimilars Market 2014-2018, says several factors could influence a projected compound annual growth rate of 27.58% in the global biologics market through 2018. The catalyst for the expected boom is an increasing number of expiring patents.
Blockbuster drugs whose patents are due to expire include Remicade, Humira, and Retuxan.
The report also notes that the risk of drug failure after launch is a key challenge for companies involved in the development of biosimilar drugs.
The full report is available through Research and Markets.
About the Author
Davy James is the associate editor of Specialty Pharmacy Times. He can be reached at djames@pharmacytimes.com.
Articles in this issue
almost 12 years ago
Biosimilars Could Save US Consumers $250 Billion Over Next Decadealmost 12 years ago
Are Extensive Clinical Studies for Biosimilars Creating Unneeded Barriers?almost 12 years ago
Gene Variant Associated with Lowered Relapse Rates in Hepatitis C Patientsalmost 12 years ago
Electronic Medical Records Identify Infants at Risk of Hepatitis C Infectionalmost 12 years ago
Hepatitis C Patients Co-infected with HIV Have Higher Risk of Liver Diseasealmost 12 years ago
Ustekinumab Trial Shows Improvements in Psoriatic Arthritis Patientsalmost 12 years ago
Psoriatic Arthritis Patients Largely Undertreatedalmost 12 years ago
Trypanophobia: Helping Patients Deal with Fear of Needlesalmost 12 years ago
Kcentra by CSL BehringNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Round-Up: Every Most Favored Nation Agreement With the Trump Administration
2
From the Pharmacy Counter to the Kitchen Cabinet: Helping Patients Choose Quality Supplements
3
Study Finds Persistent Gaps in Diagnoses for Depression and Chronic Conditions After COVID-19
4
Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes
5